Protocol for a cohort study of adolescent mental health service users with a nested cluster randomised controlled trial to assess the clinical and cost-effectiveness of managed transition in improving transitions from child to adult mental health services (the MILESTONE study) by Singh, S.P. (Swaran) et al.
 1Singh SP, et al. BMJ Open 2017;7:e016055. doi:10.1136/bmjopen-2017-016055
Open Access 
Protocol for a cohort study of adolescent 
mental health service users with a 
nested cluster randomised controlled 
trial to assess the clinical and cost-
effectiveness of managed transition in 
improving transitions from child to 
adult mental health services (the 
MILESTONE study)
Swaran P Singh,1 Helena Tuomainen,1 Giovanni de Girolamo,2 Athanasios Maras,3,4 
Paramala Santosh,5,6,7 Fiona McNicholas,8,9,10,11 Ulrike Schulze,12 
Diane Purper-Ouakil,13 Sabine Tremmery,14,15 Tomislav Franić,16 Jason Madan,17 
Moli Paul,1,18 Frank C Verhulst,4,19 Gwen C Dieleman,4 Jane Warwick,17 
Dieter Wolke,1,20 Cathy Street,1 Claire Daffern,17 Priya Tah,1 James Griffin,17 
Alastair Canaway,17 Giulia Signorini,2 Suzanne Gerritsen,4 Laura Adams,21 
Lesley O’Hara,22 Sonja Aslan,12 Frédérick Russet,13 Nikolina Davidović,16 
Amanda Tuffrey,1 Anna Wilson,1 Charlotte Gatherer,1 Leanne Walker,1 for the 
MILESTONE ConsortiumTo cite: Singh SP, Tuomainen H, 
Girolamo Gde, et al.  Protocol 
for a cohort study of adolescent 
mental health service users with 
a nested cluster randomised 
controlled trial to assess the 
clinical and cost-effectiveness of 
managed transition in improving 
transitions from child to adult 
mental health services (the 
MILESTONE study). BMJ Open 
2017;7:e016055. doi:10.1136/
bmjopen-2017-016055
 ► Prepublication history for 
this paper is available online. 
To view these files please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2017- 
016055).
SPS and HT contributed equally.
Received 20 January 2017
Revised 18 August 2017
Accepted 25 August 2017
For numbered affiliations see 
end of article.
Correspondence to
Professor Swaran P Singh;  
 s. p. singh@ warwick. ac. uk
Protocol
AbstrACt
Introduction Disruption of care during transition from 
child and adolescent mental health services (CAMHS) to 
adult mental health services may adversely affect the 
health and well-being of service users. The MILESTONE 
(Managing the Link and Strengthening Transition from 
Child to Adult Mental Healthcare) study evaluates 
the longitudinal course and outcomes of adolescents 
approaching the transition boundary (TB) of their CAMHS 
and determines the effectiveness of the model of managed 
transition in improving outcomes, compared with usual 
care.
Methods and analysis This is a cohort study with a 
nested cluster randomised controlled trial. Recruited 
CAMHS have been randomised to provide either (1) 
managed transition using the Transition Readiness and 
Appropriateness Measure score summary as a decision 
aid, or (2) usual care for young people reaching the TB. 
Participants are young people within 1 year of reaching 
the TB of their CAMHS in eight European countries; one 
parent/carer and a CAMHS clinician for each recruited 
young person; and adult mental health clinician or 
other community-based care provider, if young person 
transitions. The primary outcome is Health of the Nation 
Outcome Scale for Children and Adolescents (HoNOSCA) 
measuring health and social functioning at 15 months 
postintervention. The secondary outcomes include mental 
health, quality of life, transition experience and healthcare 
usage assessed at 9, 15 and 24 months postintervention. 
With a mean cluster size of 21, a total of 840 participants 
randomised in a 1:2 intervention to control are required, 
providing 89% power to detect a difference in HoNOSCA 
strengths and limitations of this study
 ► This is the first ever methodologically robust trial to 
test whether a decision support and assessment tool 
can improve the mental health and social outcomes 
and functioning of transition-age young people 
receiving care at child and adolescent mental health 
services.
 ► A large, prospectively identified and robustly 
evaluated cohort of young people across several 
European countries with diverse healthcare systems 
is taking part in the study.
 ► The cost-effectiveness of the intervention and 
research-related changes in health systems in terms 
of both expenditure and related health outcomes will 
be evaluated.
 ► There is a strong patient and public involvement at 
all stages of the study.
 ► Due to the nature of the intervention, it is not 
possible for clinicians or assessors to be blind to the 
allocation of clusters or of the service users within 
these clusters.
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score of 0.30 SD. The addition of 210 recruits for the cohort study ensures 
sufficient power for studying predictors, resulting in 1050 participants and 
an approximate 1:3 randomisation.
Ethics and dissemination The study protocol was approved by the UK 
National Research Ethics Service (15/WM/0052) and equivalent ethics 
boards in participating countries. Results will be reported at conferences, 
in peer-reviewed publications and to all relevant stakeholder groups.
trial registration number ISRCTN83240263; NCT03013595 (pre-
results).
IntroduCtIon
The MILESTONE (Managing the Link and Strengthening 
Transition from Child to Adult Mental Healthcare) study 
focuses on the period when young people attending child 
and adolescent mental health services (CAMHS) need to 
move on, or ‘transition’ to, an adult mental health service 
(AMHS), if they still require ongoing care.
Adolescence is a high-risk period for psychological 
morbidity, and young adulthood is the period during 
which most of the serious mental disorders that disable 
or cause death in adult life have their onset.1–4 The 
National Comorbidity Survey Replication in the USA 
found that 75% of people with a mental disorder have 
an age of onset younger than 24 years, and 50% have an 
onset before 16.5 However, only a small proportion of 
young people with mental health problems approaching 
adulthood, less than one in six, access services or receive 
appropriate care.6
There is international concern about young people 
who get ‘lost’ during their move from CAMHS to 
AMHS,7–15 and transition-related discontinuity of care is 
a major socioeconomic and societal challenge. In the UK, 
almost half of the service users reaching the transition 
boundary of their CAMHS do not go on to receive adult 
care.7 16 The Transition from CAMHS to Adult Mental 
Health Services (TRACK) study found that less than 5% 
of patients undergoing CAMHS to AMHS transition expe-
rience continuity of care.17 There is also a concern that 
despite recognition of ongoing mental health need, few 
young people are referred, with fewer than one-third in 
one study.18 Continuity of care is hampered by a multi-
tude of reasons, including differences between adult and 
child models of care; differing referral criteria; lack of a 
planned, purposeful and needs-based assessment of those 
who reach the boundary; communication and informa-
tion transfer problems between services caused partly by 
different beliefs, attitudes, mutual misperceptions and 
lack of understanding of different service structures; lack 
of shared protocols/manuals for transition; lack of shared 
client planning between child and adult systems; young 
people’s level of maturity and understanding; and adoles-
cent and/or family resistance to transition.19–21 Further-
more, transition may differ widely across different regions 
and countries due to lack of or different procedures.
Problems at the CAMHS–AMHS interface are accen-
tuated by the fact that young people are simultaneously 
negotiating developmental and situational transitions, 
such as changes in housing and relationships and moving 
on to adult roles.8 17 A lack of information about possible 
options, planning that takes too long and where no one 
professional takes charge to ensure decisions are acted 
on, compound the problem.22 Those who slip through 
the care net are likely to present to adult services at a 
subsequent time, with more severe and enduring mental 
health problems.23–25 Disruption of care during transition 
adversely affects the health, well-being and potential of 
this vulnerable group,26–31 and negative transition experi-
ences adversely impact the young person’s future engage-
ment with mental health services.32
Intervening at the level of transition represents one 
of the most important ways we can facilitate recovery 
and mental health promotion and mental illness preven-
tion in adulthood. Ensuring sustained treatment through 
the transitional period is very likely to be cost-effective, 
since the presence of mental illness during childhood 
leads to 10 times higher costs during adulthood.33–35 
However, there is currently no evidence for any effective 
model of appropriate transitional mental healthcare or 
any interventions to reduce these individual and societal 
costs.36
transitional care
Ideally, transition to adult mental health services (AMHS) 
should be a planned, orderly, purposeful and patient-cen-
tred process that ensures continuity of care, optimises 
health, minimises adverse events and ensures that the 
young person attains his/her maximum potential.37–41 
Good transitional care starts with preparing a service user 
to leave the child-centred healthcare setting and ends 
when that person is received in, and properly engaged 
with, the adult provider or an appropriate alternative, 
or is discharged from care in a planned and managed 
fashion.42 43
European research on transition from CAMHS to 
AMHS is sparse, with little information available on 
the quality of transition and transition experiences in 
different European Union (EU) countries in relation to 
long-term mental health outcomes. The organisation of 
CAMHS in the member states varies, including the age 
at which young people are transitioned to adult services, 
size and complexity, sources of funding, and service provi-
sion and care. There is some evidence though that transi-
tion is a problem across all EU states.44–46
Barriers to good transition have been mapped,16 17 but 
the evidence of interventions for improving transitional 
care is scant. A recent systematic review of CAMHS to 
AMHS transition identified only three initiatives, all in the 
USA,20 including a case management model, a transition 
support model and an outpatient transition programme. 
Although all three programmes showed improved clinical 
and social outcomes for those with facilitated transition, 
none of these was a randomised trial and each model 
was deeply rooted within its own particular and specific 
healthcare context. There is no consensus as to who 
can be discharged on reaching the CAMHS transitional 
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boundary, who should receive transitional care and how 
this care should be delivered. Furthermore, it is not clear 
what outcomes should be measured to assess clinical and 
cost-effectiveness of the model, what the outcomes of 
those who fall through the care gap are, and what the 
individual, organisational and societal costs of poor, inad-
equate or inappropriate transition are. A recent National 
Institute for Health and Care Excellence (NICE) review 
on transition from child to adult care across all specialties 
found that there was no robust evidence on models of 
transitional care.36
In the absence of a planned, purposeful and needs-
based assessment of those who reach the boundary, 
clinical judgement on transition can be influenced by 
misperceptions of other services, time and resource 
constraints, poor communication between CAMHS 
and AMHS, and poor adherence to existing policies.19 
Research has confirmed several information-gathering 
biases in unstructured clinical judgements, such as diag-
nostic biases, confirmation biases, ignoring conflicting 
information, and assumptions based on patient and 
service background.47 A recent study found that feeding 
back structured assessment results to clinicians led to 
improved clinical decision making.47
Ideally all young people who reach a transition boundary 
would be assessed in a structured and standardised way 
to determine ongoing need for care. Those who need 
such care would make a transition to adult services in a 
planned and managed manner ensuring continuity of 
care across all domains. Those without ongoing need 
would be appropriately discharged. Despite the intuitive 
simplicity and clinical importance of such a structured 
decision process, a transition model incorporating this 
approach with regard to mentally ill patients has not been 
evaluated or reported in research or health practice liter-
ature, although its need has been articulated.11 14
the MILEstonE project
The 5-year MILESTONE project (February 2014–
January 2019) aims to improve the understanding of, 
and strengthen, CAMHS–AMHS transitional care across 
different healthcare systems in the EU. In a series of 
work packages, it will (1) map current services and tran-
sitional policies across the EU; (2) develop and validate 
transition-specific outcome measures; (3) conduct a 
longitudinal cohort study of transition processes and 
outcomes across eight EU countries; (4) develop and 
test, in a cluster randomised trial, the clinical and cost-ef-
fectiveness of an innovative transitional care model; (5) 
create clinical, organisational, policy and ethics guide-
lines for improving care and outcomes for transition age 
youth; and (6) develop and implement training pack-
ages for clinicians across the EU. This paper presents 
the protocol (V.2.2) for the work packages dealing with 
the longitudinal cohort study, the cluster randomised 
controlled trial (cRCT) and the economic evaluation of 
the trial, which combined constitutes the MILESTONE 
study.
MILEstonE model of managed transition
The model of transitional care we have developed 
consists of an evidence-based decision-making process 
and managed transition, incorporating key principles of 
continuity of care: adequate information transfer, appro-
priate joint working, therapeutic and relational conti-
nuity, and engagement with adult services.48 49 The model 
of managed transition can be seen as one of the corner-
stones of a planned and purposeful transition process and 
can lead to more effective joint working between services. 
It addresses the need to involve young people and parent/
carers in the planning process, tailor transition support 
to individual needs, identify barriers to smooth transi-
tion and act on these, plan transition in a timely fashion, 
produce a succinct medical summary of the service user, 
and improve information transfer and communication 
with adult providers.36 The model includes the following:
1. The establishment and/or confirmation of shared 
understanding of criteria for good-quality transitional 
care at the CAMHS–AMHS interface, and managed 
ending of care, taking into account clinicians’ prior 
knowledge of good-quality transition.
2. Systematic identification of all young people under 
CAMHS care who reach the transition boundary for 
their service.
3. Structured and standardised assessment of their 
mental health and social care needs using a bespoke 
Transition Readiness and Appropriateness Measure 
(TRAM), completed by the young person, their par-
ent/carer if available and CAMHS clinician prior to, 
ideally 6 months before, the transition boundary.
4. Feedback of TRAM results from all parties in a short, 
clearly presented report to relevant clinicians in CAM-
HS, allowing clinicians to identify areas in which at-
tention should be focused to ease a young person’s 
path to transition.
5. Using the findings from the TRAM report to focus 
communication with service users and carers on is-
sues surrounding end of care at CAMHS and poten-
tial transition to AMHS or other community-based 
service.
6. Incorporation of critical information by clinician to 
young person’s care or transition plan, and designing 
goals for critical items that are achievable.
7. Sending the TRAM findings, along with a referral let-
ter, to the new adult service, if a referral to AMHS is 
made.
8. Structured and regular follow-up of all young people 
using the Transition Related Outcome Measure 
(TROM) to assess whether those who needed care 
were appropriately engaged with adult services and 
those who had been discharged or referred to other 
services had no unmet needs following cessation of 
care.
trAM and troM
The TRAM, a decision support and assessment tool, uses 
the HealthTrackerTM platform. The measure, together 
group.bmj.com on November 3, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
4 Singh SP, et al. BMJ Open 2017;7:e016055. doi:10.1136/bmjopen-2017-016055
Open Access 
with the linked findings report, have been designed to 
help the clinician identify (1) high-risk, high-need cases 
for whom transition to AMHS is advisable and appro-
priate, (2) those who can be appropriately discharged in 
a planned manner from CAMHS to a general practitioner 
(GP), or (3)  transitioned to another community-based 
service (such as social services, voluntary sector or other 
non-statutory agencies). Obviously, the clinicians will 
need to take their local service provision into account 
when making the decisions. The TROM provides infor-
mation on outcomes post-transition, and on the transi-
tion process and experience.
The TRAM and TROM were developed using existing 
literature, expert input and focus groups on developing 
and validating Patient Reported Outcome Measures50 51; 
MILESTONE’s group of young advisors also reviewed the 
scales and helped identify areas of duplication or unclear 
terms. The scales have been translated into Croatian, 
Dutch, Flemish, French, German and Italian languages, 
and provide a summary of all factors necessary to consider 
(including symptoms, functioning, risk and need for care) 
when making a transition decision and when assessing the 
outcomes of a transition. There are versions for young 
people pre- or post-transition, parents/carers and clini-
cians at CAMHS and AMHS, which can be completed 
online, via the HealthTrackerTM platform (https://
www. healthtracker. co. uk), a web-based portal allowing 
measures to be completed remotely that has been used in 
other EU's Seventh Framework Programme for Research 
and Technological Development (FP7)projects.52
The TRAM and TROM contain 20 questions common 
to both scales for all participants; eight additional ques-
tions are relevant only to the clinician and nine only to 
the young person and parent/carer versions. All partici-
pant versions of TRAM contain 15 additional questions 
that are not in TROM, yet to allow comparison of results 
over time, most of the domains present in TRAM are also 
present in TROM, with versions for AMHS and CAMHS 
clinicians and different follow-up time points (available 
from the corresponding author upon request).
The construct validity, content validity, inter-rater 
validity, test–retest validity and sensitivity to change of 
TRAM and TROM were assessed in a substudy between 
June 2015 and April 2016.
The ‘TRAM score summary report’ presents the scores 
from the young person, parent/carer and clinician for 
each item, with graphs visualising differences or similar-
ities in scoring. The report contains items that are rele-
vant to the clinician’s transition decision (symptoms, risk 
factors and disruption experienced by the young person) 
and those that can facilitate a smooth transition. It displays 
all information in a user-friendly, relevant and accessible 
format, helping identify young people requiring further 
care and allowing key facts to be easily transferred to care 
plans and referrals. It should complement a much more 
comprehensive evaluation, with the ultimate decision 
about transition being the outcome of a process involving 
key stakeholders.
The TRAM will be optimised on the HealthTrackerTM 
platform based on decision-making algorithms derived 
from the study. If appropriately funded, this will be 
made available to serve as the platform for optimisation 
of transitions to adult mental health in the EU.
AIMs And objECtIvEs
The overall aim of the nested cRCT is to determine 
the effectiveness and cost-effectiveness of the model of 
managed transition in improving the health and social 
outcomes of young people, and their transition to adult 
roles, as compared with treatment as usual, in eight 
participating EU countries. The specific objectives are 
the following:
1. To test the hypothesis that the implementation of 
the model of managed transition in CAMHS at the 
transition boundary improves the mental health and 
social outcomes of young people and their transition 
to adult roles when they move on from CAMHS, as 
compared with usual care.
2. To conduct an economic evaluation of the model of 
managed transition compared with usual care.
3. To explore the views and experiences of health 
professionals and young people concerning the 
intervention.
The prospective cohort study will delineate the transi-
tion journey of a large number of young people across 
eight EU countries. The aims are the following:
1. To evaluate the mental health, quality of life and 
functioning of young people who attend CAMHS and 
reach the CAMHS/AMHS transition boundary;
2. To evaluate the longitudinal course of mental health, 
social and adult functioning outcomes of young peo-
ple who reach the CAMHS/AMHS transition bound-
ary and transition into young adulthood;
3. To compare the outcomes in those young people who 
transition with those who do not transition to AMHS 
(ie, remain in CAMHS, are discharged or referred to 
other care).
MEthods And AnALysIs
study design and management
A large cohort of young people approaching the 
CAMHS–AMHS transition boundary in eight EU coun-
tries will be recruited and a nested cRCT in a randomly 
selected subset of clusters (CAMHS) will be imple-
mented. The study design is a modification of the Cohort 
Multiple Randomised Controlled Trial,53 by virtue of 
allocation to the intervention by cluster randomisa-
tion, with each distinct CAMHS comprising a cluster. 
The control arm clusters from the cRCT together with 
additional excess clusters form the longitudinal cohort 
study, with a follow-up period of 24 months. The cRCT is 
a superiority trial; the aim is to show that managed tran-
sition is superior to usual care in improving patient-re-
ported outcomes. Usual care varies by CAMHS and may 
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or may not include transitioning planning. The primary 
outcome endpoint is 15 months. The study flow diagram 
is presented in figure 1. All arms of the study undergo 
the same data collection. The trial has economic and 
qualitative components, addressing objectives 2 and 
3, respectively. Detailed Statistical Analysis Plans have 
been developed for both the cRCT and longitudinal 
cohort study. Final versions will be signed off prior to 
commencement of the analysis and made available on 
the study website.
The study is sponsored by the University of Warwick 
and coordinated from the research office in the Mental 
Health and Wellbeing unit, Warwick Medical School, with 
Quality Assurance and Statistics from Warwick Clinical 
Trials Unit. The study coordinator is responsible for the 
day-to-day coordination and the chief investigator (CI) for 
Figure 1 MILESTONE study flow diagram. AMHS, adult mental health services; CAMHS, child and adolescent mental health 
services; cRCT, cluster randomised controlled trial; MILESTONE, Managing the Link and Strengthening Transition from Child to 
Adult Mental  Healthcare.
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clinical aspects. The study is managed by a trial manage-
ment group (TMG), including work package leaders (ie, 
country leads), and supported by MILESTONE research 
staff. The TMG speaks monthly by telephone conference 
chaired by the CI. The study conduct and progress are 
overseen by the independent MILESTONE Scientific, 
Clinical and Ethical Advisory Board (SCEAB) comprising 
five international experts and four patient and public 
involvement (PPI) representatives. The SCEAB members 
are invited to the annual general meetings in order to 
monitor the progress of work, to assess the scientific 
quality and to give feedback to the Consortium members, 
but without a right to vote. The SCEAB will also review 
the main governance and any ethical issues that might 
require greater attention.
MILESTONE has strong PPI embedded throughout 
the project; young advisors, some with experience of tran-
sition in mental health services, provided feedback on the 
protocol and study documents, and designed the inter-
vention leaflet. Their ongoing role includes attending 
and contributing to project steering committee meetings, 
developing other promotional materials, and advising 
on recruitment and the engagement of young people. 
The first five PPI representatives have been from the UK; 
in the third year, service users from other participating 
countries will be involved.
setting and site selection
The study is currently running in Belgium, Croatia, 
France, Germany, Ireland, Italy, the Netherlands, and the 
UK. Recruitment of participants is underway in 52 CAMHS 
clusters that fit the inclusion criteria below (October 
2015–December 2016, with last inclusions in January 
2017). Face-to-face meetings with clinical and manage-
rial leads were arranged at those sites that expressed an 
interest and the study was explained in detail. Signed site 
agreements or equivalent were obtained from partici-
pating sites prior to the start of the study. The majority of 
sites received no funding from the EU grant (no 602442) 
for taking part in the study. However, two German 
recruiting sites received payments under subcontract to 
facilitate recruitment.
In most countries, other than the UK, there is no 
umbrella organisation to facilitate collaboration between 
AMHS and CAMHS. Furthermore, a single CAMHS may 
be linked with numerous AMHS (inpatient services, 
clinics, teams and individuals), making it difficult for 
AMHS clinicians to be engaged from the start, particu-
larly given our limited resources. Also, we were not able to 
predict which AMHS would be involved, as this is depen-
dent on transition decisions.
Cluster-level eligibility criteria
For a CAMHS to be eligible, it had to be a service deliv-
ering medical and psychosocial interventions for chil-
dren and adolescents with mental health problems and 
disorders, and/or neuropsychiatric/developmental 
disorders (eg, emotional/neurotic disorders; eating 
disorders; hyperkinetic disorder/attention deficit hyper-
activity disorder; autism spectrum disorders); communi-
ty-based, or provide outpatient or inpatient care; publicly 
or privately funded; have a formal upper age limit (the 
transition boundary) for providing care to young people; 
and be responsible for transfer of care to an adult service 
for those who reach the transition boundary. Forensic 
services and highly specialised national services, which 
cater to rare/unusual disorders and/or serve a national 
population, such as specialist clinics for rare metabolic 
disorders or long-term residential care for severe autism, 
were excluded. Eligible services could vary in size and 
complexity, ranging from single psychiatrists or psychol-
ogists (eg, Germany) or circumscribed teams, to services 
with multiple teams and localities offering multidisci-
plinary care (eg, UK).
Baseline service-level data collection
Baseline service data were collected from the CAMHS 
manager or leading CAMHS clinician at all recruited 
CAMHS in the year preceding recruitment of study 
participants. The questionnaire covered (1) size (number 
of staff), structure and function of CAMHS; (2) transition 
boundary of the service (ie, age at expected transition); 
(3) the number and type of AMHS that operate within 
the CAMHS catchment area; (4) current transition policy 
and practice; and (5) size of the catchment population. 
This information was used to establish the organisational 
structure of CAMHS and identify potential crossover 
and/or movement of staff between teams or units so that 
distinct units (clusters) could be identified. If one or 
more CAMHS teams share the same core clinicians, then 
these were classified as one cluster, becoming the unit of 
allocation.
The data revealed that the CAMHS–AMHS transition 
boundary for most countries was 18 years, that is, the 
age of majority. In the UK, Belgium and France, there 
was more variation, the boundary ranging from 15 to 18 
years. We also discovered that some services in Belgium, 
France, the Netherlands and Germany adopt a more 
flexible approach to the boundary, and in these situa-
tions we agreed a nominal boundary (18 years), which 
reflects the age at which transitions most commonly 
occur and, in most instances, is also the official transi-
tion boundary.
On leaving CAMHS care, young people may be referred 
on to AMHS or another community-based service (eg, 
social services, voluntary sector or other non-statutory 
agencies offering support and therapeutic interventions 
for mental health needs), or discharged back to their 
GP. AMHS and community-based services will be invited 
to participate in the study, and service-level data will be 
collected once they are recruited.
randomisation
As several countries only had three CAMHS clusters, this 
fixed the randomisation ratio at 1:2 and the randomisa-
tion was conducted in a two-stage process: First, randomly 
group.bmj.com on November 3, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
 7Singh SP, et al. BMJ Open 2017;7:e016055. doi:10.1136/bmjopen-2017-016055
Open Access
selected triplets of clusters within each country were iden-
tified for inclusion in the cRCT. These three clusters were 
further randomised in a 1:2 ratio between intervention and 
control arms. The excess clusters (those not selected during 
the first stage for the cRCT) were used for the cohort study 
only to enhance numbers. Overall, this two-stage process 
equates approximately to a randomisation ratio of 1:3. All 
randomisations were conducted by the trial statistician using 
the statistical software Stata V.14.54
The CAMHS were informed of their allocation after 
randomisation. The study personnel were also aware of the 
allocation as they are involved in delivering the interven-
tion and assessing outcomes. The young people and their 
parents/carers, who are recruited after randomisation, are 
informed of their allocation after they have consented to the 
study, yet only if they ask about this specifically.55
Participant eligibility and recruitment
Young people
Individual recruitment targets were set for each CAMHS 
(cluster), based on local capacity, but with the constraint 
that in the cRCT there should be on average 21 participants 
per cluster. Databases of all participating CAMHS are scru-
tinised by CAMHS personnel to identify all young people 
approaching the service’s transition boundary and meeting 
the inclusion criteria over a 15-month recruitment period 
(between October 2015 and December 2016).
Young people are eligible if (1) their age is within 
1 year of reaching the transition boundary of their 
CAMHS during the trial recruitment period and, in 
exceptional cases, not more than 3 months older than 
the transition boundary, if a decision about transition 
has not yet been made; (2) they have a mental disorder 
defined by the Diagnostic and Statistical Manuals of 
Mental Disorders, DSM-IV-TR (4th edition text revision), 
or DSM-5 (5th edition), or the International Statistical 
Classification of Diseases and Related Health Problems 
10th and 11th revisions (ICD 10/11), or they are under 
the regular care of CAMHS (attended at least one 
appointment, if not yet diagnosed); (3) they have an IQ 
≥70 as ascertained by previous standardised assessment 
or diagnosed by clinician, or no indication of intellec-
tual impairment; and (4) they provide valid written 
informed consent, or assent, if below the legal age of 
consent (in England this age is 16, in all other partic-
ipating countries 18). They are ineligible if they (1) 
are younger than a year before the transition boundary 
of their CAMHS; (2) have a more severe intellectual 
impairment (IQ <70), as ascertained by previous stan-
dardised assessment or diagnosed by clinician—if no 
data on intellectual functioning are available (because 
it has never been assessed), then care coordinators 
are asked to make a clinical judgement on intellectual 
impairment before baseline assessment takes place; (3) 
are not able to (or expected not to be able to) complete 
the questionnaires due to severe physical disabilities or 
language problems, even with assistance from family 
members or a research assistant; (4) are service users in 
a secure forensic institution; or (5) do not provide valid 
written informed consent, or assent, if below the legal 
age of consent.
At each site, the clinicians of eligible young people 
advise the research team of the ability/capacity of the 
young person to give informed, voluntary consent or 
assent. Young people are introduced to the study (as 
appropriate, taking local ethical/legal conditions and 
best practice into consideration) either by (1) a clinician 
or care coordinator, who provides a study leaflet and/
or briefing sheet and seeks consent for the individual to 
be contacted by a MILESTONE research assistant using 
a signed contact form; (2) a letter signed by their care 
coordinator or clinician outlining the purpose of the 
study followed by a phone call by a CAMHS personnel 
if no response is received; or (3) posters and/or leaflets 
displayed in the participating CAMHS sites, with contact 
details of the research team.
All young people who agree to be approached by a 
MILESTONE researcher are individually contacted 
and provided with further information about the study; 
interested individuals are asked to sign a study consent 
form. Young people who are below the legal age of 
consent are asked for their assent and signed consent 
is obtained from a parent/carer (or, in some countries, 
parents/carers, according to national medical ethics 
requirements).
A compensatory inclusion process has been factored in; 
if one country is unable to meet its recruitment target, 
another country is allowed to over-recruit.
Parents/carers
The information provided to young people includes sepa-
rate information and consent forms for their parents/carers. 
After signing up to the study, the young person is asked to 
name his/her primary caregiver, whom he/she would like 
to be involved. For young people under the legal age of 
consent, the parent/carer has to be the legal guardian of 
the young person. The aim is to engage the same parent/
carer throughout the whole study period. If the latter is not 
possible, then the aim is to involve another parent/carer. 
If the young person does not live with his/her biological 
parent/s, then his/her carer is involved. A carer may be 
the legal guardian or a partner or an older adult sibling, 
or another individual living with and/or providing regular 
support to the young person.
The parent/carer is eligible if the young person consents 
to parent/carer participation and he/she provides a 
valid written informed consent. A parent/carer is ineli-
gible if he/she does not live with and/or provide regular 
support to the young person, and/or is not able to (or 
expected not to be able to) complete the questionnaires 
due to severe physical disabilities or language problems, 
even with assistance from family members or a research 
assistant.
Young people who do not wish their parent/carer to be 
approached to participate in the study have their wishes 
respected, regardless of their own capacity to consent. If a 
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parent/carer is unwilling to participate, their wishes are 
respected.
Clinicians/care providers
Clinicians/care providers are contacted and provided 
with separate information sheets and consent forms. 
They are eligible if they are responsible for the main care 
for the young person at CAMHS (and AMHS or other 
relevant service provider, if referral is made) and provide 
a valid written informed consent.
Intervention
The CAMHS in the intervention arm receive informa-
tion on good-quality managed transition and feedback 
from the TRAM assessment in the form of a TRAM score 
summary report for each participating young person.
Information provision at CAMHS
A special meeting is held between MILESTONE personnel 
and participating CAMHS in the intervention arm prior 
to service user recruitment to establish clinicians’ existing 
Figure 2 Flow chart of study intervention (feedback of TRAM results) and follow-up assessments with young 
person. AMHS, adult mental health services; CAMHS, child and adolescent mental health services; P/C, parent/carer; RA, 
research assistant; TRAM, Transition Readiness and Appropriateness Measure; YP, young people.
group.bmj.com on November 3, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
 9Singh SP, et al. BMJ Open 2017;7:e016055. doi:10.1136/bmjopen-2017-016055
Open Access
knowledge and current practice of transition, and to 
discuss optimal transition, using TRAM as a decision 
support tool, and managed ending of care. Each meeting 
follows a prescribed structure. Additionally, written infor-
mation on good-quality transitional care is provided to all 
clinicians in the intervention arm CAMHS teams. This 
consists of presentation handouts and a leaflet on good-
quality transition designed by our young project advisors.
Feedback of TRAM results
The aim is to conduct the TRAM assessment approx-
imately 6 months prior to the transition boundary. The 
TRAM findings (TRAM score summary report) are fed 
back to clinicians soon after the young person, parent/
carer and CAMHS clinician have completed the baseline 
assessments.
1. The TRAM results are communicated to the CAMHS 
clinician in a secure fashion via an email, attaching 
the TRAM score summary report (which contains no 
identifiable information), and an offer is made to 
explain the findings at a face-to-face meeting. If no 
response is received, the email is followed up once 
only with a telephone call.
2. The CAMHS clinician is encouraged to communicate 
the TRAM findings to the young person and parent/
carer, and incorporate critical information to young 
person’s care or transition plan, and design goals for 
critical items that are achievable.
3. The CAMHS clinician decides whether or not to refer 
the young person to adult services.
4. If a referral is made, the CAMHS clinician is asked, 
if appropriate and with relevant permissions, to send 
the TRAM score summary report along with the refer-
ral letter to the new adult service.
5. The AMHS clinician or other care provider is offered 
a chance to discuss the TRAM findings with an 
appropriate member of the MILESTONE research 
team.
The aim of the TRAM score summary report is to 
support clinicians in their decision making regarding 
transition, communication with stakeholders and plan-
ning of the transition process. A flow chart of the study 
intervention is depicted in figure 2.
The control arm
Young people, parent/carers and clinicians in the control 
arm complete the same baseline assessments, but the 
latter do not receive any additional training or feedback 
of TRAM scores, that is, continue providing usual care, 
which may or may not include transition planning.
outcome measures
Primary outcome measure
The primary outcome measure is the clinician-rated 
Health of the Nation Outcome Scale for Children and 
Adolescents (HoNOSCA),56 which has 15 items scored on 
a scale of 0–4, and covers the severity of the behaviour, 
impairments, symptoms and social functioning of 
children and young people with mental health problems. 
The clinical usefulness of the HoNOSCA has been vali-
dated and its sensitivity to change confirmed.57 58
Although the HoNOSCA is intended as a measure that is 
completed by a clinician who is also responsible for treat-
ment of the client, the measure can also be completed 
by a mental healthcare professional not involved in the 
treatment using semistructured interview.59 In our study 
the measure is completed by a trained MILESTONE 
research assistant by interviewing the young person and 
taking into account all other available sources of infor-
mation (parent/carer, relevant clinician and the medical 
records) to ensure accuracy of data.
To ensure consistency and comparability, HoNOSCA is 
used throughout (rather than switching to HoNOS at age 
18 years). The primary outcome endpoint for the cRCT 
is 15 months.
Secondary outcome measures
The secondary outcome measures are as indicated in 
table 1. Apart from the TROM, two others were devel-
oped specifically for the MILESTONE study.
The Ethics of Transitioning questionnaire was devel-
oped based on the themes raised by a systematic litera-
ture review and focus groups and addresses the following 
research question: ‘What are the ethical challenges 
of ensuring delivery of transitional care to those who 
need it most against the risk of pathologising transient 
and self-limiting distress and dysfunction, which may 
be normal during adolescence?’ It contains seven items 
rated on a 5-point Likert scale, with one version to be 
completed prior to, and another after, transitioning.
The Life Events questionnaire is a dichotomous 13-item 
scale that is appropriate for both young people and adults, 
and focuses on significant life events, such as accidents, 
deaths in the family and separation of parents/carers.
data collection
Data collection is the same in the intervention, control 
and cohort arms of the study.
Baseline data
Table 2 highlights the number of contacts with the partic-
ipants, the time points of the various assessments, and 
the type of data to be collected from the young person, 
parent/carer and clinician.
The baseline assessment (T1) is undertaken after 
consent/assent has been given but before the delivery of 
the intervention, within 6 months before the transition 
boundary of the service or, in exceptional cases, within 12 
months before or 3 months after the boundary (eg, if tran-
sitions regularly happen earlier in a service or a decision 
about transition has not yet been made). Young people 
and their parents/carers are assessed at the clinic, or at 
an alternative location suitable for the young person, with 
both semistructured interview (sociodemographic and 
personal information, and HoNOSCA) and online assess-
ment. The sociodemographic and personal information 
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Table 2 Study assessments for participants (transition scenario)
Contact 1 2 (T1) 3 (T2) 4 (T3) 5 (T4)
Contact window (Number of 
months±number of months)
Within 6 months 
before TB‡
9 months 
(±1 month) after 
T1
15 months 
(±1 month) after 
T1
24 months 
(±1 month) after 
T1
Inclusion/exclusion criteria YP
P/C
Informed consent YP
P/C
YP
P/C
C
(YP)
(P/C)
C
(YP)
(P/C)
(C)
(YP)
(P/C)
(C)
Contact details YP
P/C
YP
P/C
YP
P/C
YP
P/C
YP
P/C
Sociodemographic and personal 
information
YP
P/C
C
YP
(C)
YP
P/C
(C)
YP
P/C
(C)
Need for care (HoNOSCA—SR)
(HoNOSCA—clinician report)
YP
RA (C; YP; P/C)
YP
RA (C; YP; P/C)
YP
RA (C; YP; P/C)
YP
RA (C; YP; P/C)
Transition readiness/transition outcome 
(TRAM/TROM)
YP
P/C
C
YP
P/C
C
YP
P/C
C
YP
P/C
C
Referral and transition status (CAMHS 
clinician only)
C (C) (C)
Quality of life (WHOQOL-BREF) YP YP YP
Cost-effectiveness (EQ-5D-5L) YP YP YP YP
Service use (CSRI) YP YP YP YP
Emotional/behavioural problems
(YP: YSR/ASR; P/C: CBCL/ABCL)
YP
P/C
YP
P/C
YP
P/C
YP
P/C
Ethics of Transitioning YP YP YP
Independent behaviour† (IBDCS) YP YP YP YP
Barriers to Care (BtC)† YP YP YP
Bullying YP YP
Life events YP YP YP YP
Illness perception (B-IPQ) YP YP
Transition experience and readiness 
(OYOF-TES)*
YP
P/C
(YP)
(P/C)
(YP)
(P/C)
Functioning and impairment (SLOF) P/C P/C P/C
Illness severity (CGIS) C (C) (C) (C)
Psychopathology
(YP: DAWBA 5–17/18+SR)
(P/C: DAWBA 5–17/18+PR)
C: Clinical diagnosis
 
YP
P/C
C
 
(C)
 
(C)
 
YP
P/C
(C)
T1: CAMHS clinician; if YP is transitioned after T1, then at T2–T4, the clinician is based at AMHS. If there is a delay in transitioning, the 
clinician at T2–T4 will still be based at CAMHS. Consent and sociodemographic data are sought from the clinician only once. (C)=if YP is a 
mental health service user, then clinician is asked for information.
*Completed only once at the first assessment after transition.
†If the YP is a service user, the IBDCS is administered; if the YP is not a current service user, the BtC is administered.
‡In exceptional cases, the assessment can take place up to 12 months before or 3 months after the TB (eg, if transitions regularly happen 
earlier in a service or a decision about transition has not yet been made).
ABCL, Adult Behavior Checklist; AMHS, adult mental health services; ASR, Adult Self Report; B-IPQ, Brief Illness Perception Questionnaire; 
C, clinician; CAMHS, child and adolescent mental health services; CBCL, Child Behavior Checklist; CGIS, Clinical Global Impression Severity 
scale; CSRI, Client Service Receipt Inventory; DAWBA, Development and Well-Being Assessment; EQ-5D-5L, EuroQol health questionnaire; 
HoNOSCA, Health of the Nation Outcome Scale for Children and Adolescents; IBDCS, Independent Behaviour During Consultation Scale; 
OYOF-TES, On Your Own Feet: Transition Experience Scale; P/C, parent/carer; PR, parent report; RA, research assistant; SR, self-report; 
TB, transition boundary of service; TRAM, Transition Readiness and Appropriateness Measure; TROM, Transition Related Outcome Measure; 
WHOQOL-BREF, WHO Quality of Life Brief Inventory; YP, young person; YSR, Youth Self Report. 
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questionnaire for young people and parent/carers 
collects general information about the young person 
and family, and the care the young person receives. The 
questionnaire covers also medical history and additional 
variables previously shown to contribute to continuity 
of mental health problems (eg, history of mental health 
problems and alcohol or drug abuse by parents). The last 
online assessment of T1 is the structured sections of the 
Development and Well-Being Assessment (DAWBA),60 61 
which obtains information on mental health. Information 
from the assessment with the young person and parent/
carer will be combined with a computer algorithm that 
provides an estimate of the probability of a certain indi-
vidual diagnosis. Information on clinical diagnosis is 
obtained from the clinician.
The length of the baseline assessment (young people) 
is approximately 1.5–2 hours. The participant can take 
a short break in between the online measures, and if 
required, complete them over multiple sessions. The 
research assistant is available to assist if there are any 
difficulties. The baseline assessment (T1) should be 
completed before the end of the recruitment period.
Follow-up data
Outcomes are measured 9 months (T2), 15 months (T3) 
and 24 months (T4) after T1. The aim is to complete 
measures at T2 and T3 via telephone and online assess-
ment, and at T4 via face-to-face contact with young people 
and their parents/carers, within a month (±) of the calcu-
lated assessment time point (table 2). Assessments with 
CAMHS or AMHS clinicians (or other service provider), 
which are dependent on transition status, follow the same 
schedule.
Evaluation of the intervention and experiences of young people 
regarding services
The views and experiences of CAMHS clinicians in the 
intervention arm are captured using a semistructured 
questionnaire. All clinicians are approached and those 
willing to engage are interviewed over the telephone or 
face to face.
A subsample of young people taking part in the study 
will be invited to take part in focus groups at T4 from 
three participating countries: Ireland, UK and Croatia. 
The purpose of the focus groups will be to explore their 
experiences of leaving CAMHS, transition to AMHS if 
applicable and views of mental health services, the aim 
being to establish whether young people have better 
health, educational and social outcomes, better quality 
of life, and satisfaction with services if they (1) have 
experienced a managed transition from child to adult 
services at the transitional boundary or (2) have expe-
rienced usual care (ie, their transition to adult services, 
or their discharge from services, is via the usual proce-
dure of their CAMHS clinic). It is hoped that, as part of 
MILESTONE’s PPI activity, some of the young advisors, or 
other young people trained in facilitation skills by some 
of the research sites, may cofacilitate these focus groups.
Three audio-recorded focus groups will be held in each 
country with 9–12 young people in each group. Recruit-
ment will be from the study participants with purposive 
sampling to include some young people who (1) did not 
transition to adult services, (2) who transitioned to adult 
services via usual care and (3) who experienced managed 
transition.
sample size
Assuming an average cluster size of 15 participants, an 
allocation ratio of 2:1 (control:intervention), a coefficient 
of variation of cluster size of 0.4 (cluster sizes ranging 
from approximately 5 to 30), and an intracluster correla-
tion coefficient of 0.01, with 600 participants (195 inter-
vention arm (13 clusters), 405 control arm (27 clusters)), 
the cRCT has 89% power to detect a difference of 0.30 SD 
in the primary outcome measure (HoNOSCA). To allow 
for 30% dropout, the required average cluster size is 21 
participants. Thus, for the cRCT the target sample size is 
840 participants in total (273 intervention—13 clusters of 
size 21; 567 control—27 clusters of size 21). The rando-
misation was stratified by country, with the number and 
size of clusters dictated by local capacity. Excess clusters 
(those not required for the cRCT) were allocated to the 
control arm and will be used in the analysis of the cohort 
study only to enhance numbers for sufficient power to 
study predictors for the longitudinal course and outcome 
of mental health during transition. There are 10 such 
excess clusters (average size 21 before dropouts). The 
recruitment target for the cohort study is therefore 777 
participants (567 from the control arm of the cRCT plus 
210), and the total recruitment target is 1050 (840 plus 
210).
retention of study participants
To ensure that contact is not lost with any members of 
the study population during the follow-up period and 
that data are as complete as possible, MILESTONE 
has paid considerable attention to its engagement and 
retention strategies, drawing extensively on the advice 
and experiences of its young advisors to create a special 
‘Bonding Plan’. Participants may be contacted using 
several methods of communication (post/phone/email); 
contact details of all participants, including GP and 
CAMHS clinician details, are recorded in a ‘keeping in 
touch’ form; data are collected in several different ways 
(face to face, online, phone); and each contact, or contact 
attempt, made with participants is recorded in a bespoke 
contact log. There are multiple contact points between 
study assessments, where the participants can advise of 
any changes to their contact details. The Bonding Plan 
activities vary by country, taking local ethical and cultural 
requirements into consideration. Items include thank 
you cards, newsletters, gift vouchers and a chance to win a 
prize in a lottery. The value of gift vouchers provided after 
assessments range from £10 to £20 or similar equivalent 
in euros. In Italy and Croatia, the research ethics commit-
tees did not allow providing any gifts after the individual 
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assessment time points. Reasonable travel expenses are 
reimbursed for young people and their parents/carers.
Losses to follow-up
Due to the characteristics of the study population group 
(young people, highly mobile, in the process of moving 
on to higher education, training or work), we have 
allowed for a 30% dropout rate.
Withdrawal of young people from the study
All participants remain in the study and follow-up data 
are sought unless consent for participation in data collec-
tion is explicitly withdrawn.
data analysis
Detailed Statistical Analysis Plans, which include specific 
methods of analysis for each outcome variable, have been 
developed individually for both studies, and final versions 
will be reviewed and approved by the TMG and made 
available on the study website (http://www. milestone- 
transitionstudy. eu/).
Sensitivity analyses using multiple imputation will be 
conducted to explore the potential impact of missing 
data.
Cluster randomised controlled trial
Basic descriptive methods will be used to present the data 
on study participants, trial conduct, clinical outcomes 
and safety (in total and for each study group separately). 
The primary outcome will be HoNOSCA score at T3, and 
we will test the hypothesis that there is no difference in 
this between the managed transition and standard care 
arms over the study period using a multilevel model with 
random effects to account for clustering and repeated 
measures, and adjustment for design factors (country and 
size of service). Where appropriate, a similar approach 
will be applied to the analysis of secondary outcomes. All 
analyses will be on an intention-to-treat (ITT) basis.
Cohort study
Baseline, longitudinal course and outcome data at T4 
will be analysed. Trajectories of mental health, subjective 
need for care and quality of life will be determined using 
mixed growth models and related to whether transitions 
from CAMHS to AMHS took place.
Data will be analysed to predict and characterise those 
with higher primary and secondary outcome scores. 
Functional, clinical and quality of life outcomes will be 
assessed in those CAMHS users who transition with those 
who do not transition to AMHS.
Economic evaluation
Health economic data collection
To conduct the economic evaluation of the trial, infor-
mation on healthcare usage, social care usage/social 
costs and intervention costs will be captured. Addition-
ally, participant health-related quality of life (HRQL) and 
HoNOSCA score will be recorded.
Resource use data collection
Health and social care resource utilisation for both trial 
arms will be estimated using the MILESTONE-specific 
Client Service Receipt Inventory (CSRI), which draws 
on a CSRI used previously to estimate mental healthcare 
costs in the UK,62 but has been substantially revised for 
use in MILESTONE. It includes questions regarding 
healthcare usage, and relating to social and judicial 
resource use, and these questions are tailored for each 
participating country to reflect local services. Young 
people complete the measure at all four time points. For 
the purpose of economic evaluation, a questionnaire on 
the burden and impact of TRAM will be completed by 
all clinicians within the cRCT. This will assess how much 
extra burden is placed on staff involved within the tran-
sition process due to the intervention compared with 
usual care.
The intervention costs associated with managed tran-
sition include the cost of implementing, as well as the 
delivery of the intervention. Questionnaires have been 
distributed to researchers in each country to ascertain the 
resources required to set up the intervention, while Excel 
logbooks capture the time spent by clinicians completing 
the TRAM. Likewise, the time spent by the University of 
Warwick preparing the TRAM report is logged within an 
Excel database, and clinician questionnaires will be used 
to capture the impact of the intervention on resource use.
Outcomes for economic evaluation
The two primary outcomes for the economic evaluation 
are quality-adjusted life years (QALYs) and HoNOSCA 
score.56 57 HRQL will be measured using the EuroQol 
health questionnaire (EQ-5D-5L),63 and index scores64 
will be applied to calculate QALYs to determine the 
impact of the intervention on HRQL. Changes in QALYs 
and HoNOSCA score between the two trial arms will be 
examined in conjunction with the costs to examine the 
cost-effectiveness of the intervention on mental health.
Economic evaluation: analysis
General principles of the economic analysis
Intention to treat: As recommended by best practice,65 
an ITT framework will be adopted. For each individual 
within the trial, the analysis will be conducted according 
to which arm they were randomised.
Perspective: The base-case analysis will adopt a health-
care and personal social services perspective in accordance 
with NICE recommendations.65 Given the widespread 
acknowledgement of the wider costs of poor mental 
health,66 a societal perspective will be adopted as a 
secondary analysis. Societal costs will include social care, 
productivity and criminal justice system contacts.
Time horizon: The base-case analysis will be a trial-based 
analysis and therefore consider just the years followed 
up within the trial. Given the complexity of the trial, the 
potential for long-term decision modelling and extrap-
olation will be informed by a systematic review of the 
methods used within existing mental health literature. 
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Long-run extrapolation will therefore be considered in 
light of this.
Discounting: As recommended by NICE,65 all costs and 
outcomes that occur after the first year of the trial will be 
discounted at 3.5%.
Missing data: 67 Should missing data be prevalent, 
the health economics analysis will address missing data 
through the use of multiple imputation.67
Clustering: The hierarchical nature of the data needs to 
be addressed within multiple imputation procedures and 
within the analysis framework. To do this, random effects 
approaches will be used.68
Uncertainty: The uncertainty around the results will be 
assessed through sensitivity analyses and the generation 
of cost-effectiveness acceptability curves.69
Calculating costs for economic evaluation
Data on staff time and other resources in the transition 
process will be obtained at each location, and costed 
using appropriate sources of unit cost data (eg, for the 
UK, standard unit cost sources include the National 
Health Service (NHS) reference costs and the Unit Costs 
of Health and Social Care report published annually by 
the Personal Social Services Research Unit at the Univer-
sity of Kent). This will result in location-specific estimates 
of the direct costs involved in implementing the managed 
transition process.
Outcomes for economic evaluation
The primary economic analysis will be a cost utility anal-
ysis. The EQ-5D-5L measure allows the calculation of 
QALYs. These will be calculated for each young person 
within the trial using the trapezium rule to calculate the 
area under the curve. An underlying assumption of this 
methodology is that there is a linear line between each 
utility value at each follow-up. When analysing incre-
mental QALYs between trial arms, it is important to adjust 
for baseline differences in utility70 and to account for the 
hierarchical nature of the outcome data.68 The base-
case analysis of effectiveness will therefore use methods 
that incorporate a random-effects regression model 
controlling for baseline health status and accounting 
for clustering.68 EQ-5D-5L tariffs for each participating 
country, where available, will be used to allow for coun-
try-specific economic analyses. The cost-effectiveness 
of the intervention over the duration of the trial will be 
examined, and decision uncertainty assessed using prob-
abilistic sensitivity analysis and scenario analysis.
data management
Online data collection
All measures apart from DAWBA are completed 
using HealthTrackerTM, which allows measures to be 
completed remotely using developmentally appro-
priate interfaces. It also enables participants to skip 
modules if they do not score on screening questions 
for that module, thereby reducing the time needed for 
completion. Each questionnaire has been optimised 
for the screen, based on feedback from service users 
and providers. HealthTrackerTM automatically gener-
ates random participant (service user, parent and clini-
cian) ID numbers and passwords when the participant 
is entered onto the system. HealthTrackerTM stores 
participants’ month and year of birth. All other data are 
anonymised.
The DAWBA is completed using the website http:// 
dawba. net and anonymised scores (identified and 
linked using the unique DAWBA ID) are transferred 
to a bespoke form on the HealthTracker system. A 
secure database developed at Warwick Medical School 
stores information that is not collected by HealthTrack-
erTM. This includes participant name, unique study 
ID, HealthTracker and DAWBA IDs, contact details, 
information linking participants (eg, young person to 
CAMHS clinician) and service-level information. This 
database is maintained locally at sites with access pass-
word-controlled and strictly limited to MILESTONE 
personnel to ensure confidentiality. No personally iden-
tifiable information relating to participants leaves the 
local site. Only the unique identifiers, linking informa-
tion (using identifiers) and service-level data are shared 
with Warwick Medical School.
Paper copies of measures are only used as a last resort, 
or if preferred by the participant. All MILESTONE 
researchers have received training on the HealthTrack-
erTM platform and other systems for data collection prior 
to the study beginning.
Data transfer
All transfers of study data are informed by and comply with 
the European Parliament and the Council of Europe’s 
Directive 95/46/EC on protection of individuals with 
reference to the handling of personal data and on the 
free flow of such information between EU countries.
To ensure the security and integrity of data during such 
transfer, an appropriate documented standard procedure 
has been established and will befollowed without excep-
tion. Any study data that are to be transferred between 
research sites are anonymised prior to transfer.
Data storage
All essential documentation and trial records are stored 
by Warwick Medical School and participating local sites 
in conformance with the applicable regulatory require-
ments with access to stored information restricted to 
authorised personnel.
Data access and quality assurance
In all partner countries, local research ethics committee 
requirements and national and EU law underpin the 
collection, recording, sharing and secure storage of 
person identifiable data.
Personal information about potential and enrolled 
participants is collected, shared and maintained in 
a manner that protects their confidentiality before, 
during and after the trial. All researchers working on 
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the MILESTONE study are experienced in undertaking 
research in a way that maintains the privacy and confi-
dentiality of study participants but which balances these 
demands against the need to ensure that participants 
are not at risk. Names or addresses of participants are 
not disclosed to anyone other than the staff involved in 
running the trial.
Data are only accessible by authorised personnel and 
made available to relevant bodies for audit purposes only.
At the end of the MILESTONE project, analysis 
data sets will be made available following University of 
Warwick’s Research Data Management Policy, which 
ensures that data produced through the university’s 
research activities are registered, stored, made acces-
sible for use and reuse as appropriate, managed over 
time and/or disposed of, according to legal, ethical, 
funder requirements and good practice (http:// www2. 
warwick. ac. uk/ services/ rss/ researchgovernance_ ethics/ 
research_ code_ of_ practice/ datacollection_ retention/ 
research_ data_ mgt_ policy/).
Archiving
Data from this study will be retained intact in an appro-
priate format and storage facility for a minimum of 10 
years in the UK in line with the Medical Research Coun-
cil’s guidelines on Personal Information in Medical 
Research; other countries will follow their relevant 
guidelines (http://www. mrc. ac. uk/ documents/ pdf/ 
personal- information- in- medical- research/).
Monitoring
UK sites are monitored by Warwick Medical School. 
Monitoring includes compliance to the protocol, quality 
of data collection and storage of documentation, and 
requires monitors to have access to relevant participant 
notes/charts and trial documentation. Each overseas 
party is responsible for monitoring its sites according to 
local procedures.
Adverse event management
A young person experiencing adverse events as a direct 
consequence of the intervention is unlikely, as the inter-
vention is aimed at the clinician. At each study assess-
ment, the young person is asked whether any adverse 
events (bad or unfavourable medical occurrence) have 
occurred since the last time point. This includes events 
from the first trial-related activity after the participant has 
signed the consent form until the endpoint of the trial as 
defined in the protocol. Any worsening of concomitant 
illness or new illness is recorded as adverse events at each 
visit. If the event is classified as a serious adverse event 
(SAE), an SAE form is completed and the principal inves-
tigators of each country report all SAEs immediately to 
the trial coordinating centre at Warwick Medical School. 
The trial CI determines whether SAEs require reporting 
to the trial sponsor or SCEAB.
EthICs And dIssEMInAtIon
Ethics and research and development governance
The study has been approved by the National Research 
Ethics Service in the UK (West Midlands—South 
Birmingham Research Ethics Committee, Ref no 15/
WM/0052) and by the research ethics committees of all 
partaking countries. Regional and site-specific approvals 
have been obtained from NHS Research and Develop-
ment offices in the UK and from other similar bodies 
in the other countries. The study is registered with 
the International Standard Registered Clinical/soCial 
sTudy Number (ISRCTN) registry (ISRCTN83240263) 
(http://www. isrctn. com/ ISRCTN83240263? q= MILE-
STONE& filters=& sort=& offset= 3& totalResults= 21& 
page= 1& pageSize= 10& searchType= basic- search) 
and  ClinicalTrials. com (NCT03013595) (https:// 
clinicaltrials. gov/ ct2/ show/ NCT03013595? term= 
NCT03013595& rank=1).
The ethical conduct of the study is monitored 
throughout by the MILESTONE ethics work package.
service users
We are involving a potentially vulnerable population in 
research: adolescent mental health service users, most 
of whom are over the age of 16, but in areas where the 
transition boundary is 16 years (some parts of England) 
or 16.5 years (some parts of France) they are 15 years of 
age. In England, the legal age of consent is 16, whilst in 
all other participating countries it is 18.
Despite best efforts, vulnerable people, either by 
virtue of being young and/or with mental health diffi-
culties, are often omitted from research studies because 
of concerns regarding informed consent.71 72 The 
researchers in this study acknowledge these concerns 
and risks but also recognise the importance of including 
individuals with enduring mental health difficulties in 
the study to better inform practice. The Council of 
Europe strongly promotes the participation of children 
in decisions affecting them.73 Young people also have 
rights as service users to expect appropriate and good-
quality services.
The participant information sheets and consent/assent 
forms make explicit the voluntary nature of young people’s 
involvement. Even if the parent/carer gives consent but a 
young person refuses, that young person is not included 
in the study. The young person’s consent is sought before 
follow-up assessments (verbal consent for telephone 
interviews), consent being implicit when they log on to 
give responses online. The forms also seek permission to 
delay data collection until a later point should a young 
person become unwell or due to some other pressing 
circumstances, as long as transition does not take place in 
the meantime. The forms explain the various safeguards 
in place, namely to liaise with a young person’s clinician 
and/or family, if required, and the resulting impact on 
confidentiality.
In order to minimise any distress to young people 
taking part in face-to-face interviews, wherever possible 
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these are organised at a time and place convenient 
to the young person when there are familiar staff or 
a parent/carer on hand to offer support should a 
young person become upset during any data collec-
tion processes.
In the event that during an assessmenta MILE-
STONE researcher identifies any situation where 
a young person is thought to be at risk of abuse or 
neglect, or the young person discloses information 
that raises concern about theirsafety, then a detailed 
risk management plan is followed, which stipulates 
that the child protection policies and procedures 
applicable to that country are adhered to. This is 
likely to involve close liaison by the researcher and 
the MILESTONE lead for that study site, with the 
young person’s clinician and/or the nominated child 
protection leads within the mental health service 
attended by the young person. Also, young people 
consenting to the study are asked to nominate and 
provide contact details fora health/care professional 
(eg, GP or CAMHS clinician) who can be contacted 
should any adverse event arise. This safeguard is made 
explicit in the study information leaflets, and at all 
data collection time points.
training
All research assistants have participated in training 
sessions addressing good clinical practice, transition 
practices, rating procedures, compliance, TRAM feed-
back, and communication with young people, fami-
lies and clinicians. A special focus of the training has 
been the primary outcome measure, the clinician-rated 
HoNOSCA, completed by research assistants. The 
training has included ratings and discussions of clinical 
vignettes and how to conduct the HoNOSCA interview.74 
The study has been presented to all participating CAMHS 
teams and additional meetings have been held to imple-
ment the specific transition procedures in the interven-
tion clusters.
dissemination
The MILESTONE project has a work package that 
focuses on dissemination. Partnerships and networks with 
target bodies will be strategically developed to support 
both short-term and long-term dissemination of the 
MILESTONE study and other project findings. External 
dissemination will target the scientific community, but 
also the general public, lay and patients’ associations, 
healthcare authorities and caregivers, scientific societies 
and professional boards, students, policy makers, and the 
pharmaceutical industry. Particular attention will be paid 
to the information needs of the various target audiences, 
ensuring that they are addressed in the appropriate 
language and format.
The results of the MILESTONE study will first be made 
available to the clinicians of partaking CAMHS and AMHS 
, and then to the scientific community at large via publica-
tions in scientific journals, presentations at meetings, the 
MILESTONE website (http:// milestone- transitionstudy. 
eu), press releases and leaflets.
ConCLusIon
The continuity of adolescent psychopathology into 
adulthood means that transition to AMHS is neces-
sary for many. However, there are real gaps in mental 
healthcare provision at this crucial stage, and those 
who experience transition frequently describe it as 
disruptive. The MILESTONE study is the first ever 
methodologically robust trial to test whether a deci-
sion support and assessment tool, the TRAM, can 
improve the mental health and social outcomes and 
functioning of transition age young people receiving 
CAMHS care. Young people in eight European coun-
tries are partaking in the trial and  their longitudinal 
course of mental health, social and adult func-
tioning outcomes are evaluated as part of a prospec-
tive cohort study. The MILESTONE study has crucial 
input from young advisors, some with experience of 
transition in mental health services. Overall, this is an 
ambitious and challenging study which will provide a 
timely and valuable insight into an under-researched 
population.
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